Biotech Values

[DonShimoda]

There would seem to be only two (overlapping) cohorts where there might be enough data to get subgroup-specific FDA approval: i) chronic phase; and ii) T315I+.

True, but based on the P1 results, having separate cohorts for CP and T315I pts really gives them the best chance for quick approval. Think of the other cohorts as "stretch" goals :)